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Abstract
The human papillomavirus (HPV) is a sexually transmitted virus that is most commonly found in
sexually active adolescents and young adults. Vaccination rates for HPV in the United States are
very low compared to other recommended vaccines for this age group. The literature was
reviewed to identify the reasons why adolescents and young adults, both male and female, are
not receiving the HPV vaccine in the time frame recommended by the Center for Disease
Control (CDC). Electronic databases, including CINAHL and PubMed were searched to help
locate research studies and systematic reviews that would help to identify why adolescents and
young adults are not receiving the HPV vaccine. The research studies and systematic reviews
that were utilized in this review of literature were published between 2006 and 2016, since this is
the time frame when the first HPV vaccine had been approved. The key reasons for not receiving
the HPV vaccine that were identified, included: cost and time to complete the series, safety and
efficacy, knowledge deficit regarding the vaccine and disease, provider knowledge and
recommendations of HPV vaccine, vaccine not required for school admission, religious and
cultural beliefs, concerns about increased sexual promiscuity with initiation of vaccine, and
attitudes of distrust of the vaccine due to pharmaceutical companies financial gain.
Keywords: human papilloma virus (HPV), vaccine, attitudes, barriers, concerns,
adolescents, young adults

BARRIERS TO RECEIVING THE HUMAN PAPILLOMA VACCINE

4

Identifying the barriers to receiving the human papillomavirus (HPV) vaccine in
adolescents and young adults to help increase vaccination rates in the United States.
Human papillomavirus (HPV) is a sexually transmitted infection (STI) passed through
skin-to-skin sexual contact, including vaginal, oral, and anal sex, and is the leading cause of
cervical cancer in women in the United States. HPV can affect both females and males, but is
more prevalent in young adults. HPV is spread through sexual contact and is most preventable
through vaccination (Centers for Disease Control and Prevention, 2015). Most HPV infections
will clear without intervention in one to two years, but some infections remain and can progress
to pre-cancerous lesions (Holman et al., 2014). HPV most commonly causes cervical cancer, but
is also responsible for vulvar and vaginal cancers in women. HPV is responsible for penile
cancer in males, and also causes anal, oropharyngeal cancers and pre-cancers along with genital
warts and recurrent respiratory papillomatosis in both genders (Centers for Disease Control and
Prevention, 2015).
HPV has affected about 79 million Americans, and there are about 14 million new cases
each year. HPV is so common that most sexually-active men and women will be positive for a
least one type of HPV during their lifespan (Centers for Disease Control and Prevention, 2016).
The Centers for Disease Control and Prevention (CDC) (2016) recommends that both genders
should be vaccinated against HPV starting at age eleven or twelve and if they have not received
it as adolescents, it should be recommended as a catch-up vaccine for females through age 26
and males through age 21. The recommendation for gay or bisexual men is through age 26
(Center for Disease Control and Prevention, 2016).
There is no definitive test to find out a person’s HPV status. Most individuals affected
with HPV do not even know they have it and will never develop symptoms. The vast majority of
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HPV infections will clear on their own without any intervention (Ratanasiripong, 2012).
Females are routinely screened for HPV at the age of 30 and over. Women are usually unaware
that they have the virus until their Pap smear comes back abnormal. Some individuals will
discover that they have the virus when they develop genital warts. There are about 360,000 new
cases of genital warts each year, along with 11,000 women per year that are diagnosed with
cervical cancer (Centers for Disease Control and Prevention, 2016).
The HPV vaccine is a series of three injections. The first dose is recommended at the age
of eleven or twelve, then the second dose is given one to two months after the first, and the third
dose is given six months after the first dose (Centers for Disease Control and Prevention, 2013).
The vaccine is routinely given at age eleven or twelve because optimal efficacy is derived if it is
administered before the onset of sexual activity, and because antibody responses are highest
between age nine and fifteen (American Academy of Pediatrics, 2012). The vaccination rates in
the United States in 2014 were 39.7% and 21.6% respectively for girls and boys; these numbers
reflect individuals who received all three doses of the vaccine (Centers for Disease Control and
Prevention, 2015).
There are over 100 types of HPV, about 40 of them are sexually transmitted, and 13 can
potentially cause cancer. There are currently three HPV vaccines that the CDC recommends.
HPV4 (Gardasil 4) was the first vaccine for HPV and was introduced in 2006 for females and in
2009 for males. The HPV4 vaccine protects individuals against types 6, 11, 16 and 18. Types 6
and 11 are responsible for about 90% of anogenital warts. Type 16 is being detected in 90% of
oropharyngeal cancers, and is the type that causes most cervical cancers. HPV2 (Cervarix) was
introduced in 2009 and it protects against strain 16 and 18, which are responsible for 66% of
cervical cancers and the majority of other HPV-attributable cancers. Types 16 and 18 are
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considered the high-risk oncogenic types of HPV. HPV9 (Gardasil 9) is the third vaccine, and
was introduced at the end of 2014. HPV9 protects against type 6, 11, 16, 18, 31, 33, 45, 52, and
58. The five strains that were added to the HPV9 vaccine are identified as high risk strains that
are responsible for 15% of cervical cancers, but the HPV9 vaccine will protect an individual
against 90% of potential cancers (American College of Pediatricians, 2016). Risk factors for
persistent oncogenic HPV infection include smoking, HPV type, increasing age, lack of condom
use, immunodeficiency, possible other sexually transmitted infections, and oral contraceptive
use. High-risk oncogenic infections will lead to cervical cancer and negative health outcomes in
10% of women who contract high-risk HPV types (Ratanasiripong, 2012).
It’s important to identify why the vaccination rates are so low and what providers can do
to help increase the rates. Providers should understand the most common reasons why
individuals are not getting vaccinated against HPV. Increasing the vaccination rate can help
prevent oral and anogenital warts and most importantly cancer. Most parents along with their
adolescents and young adult children experience different attitudes about receiving the HPV
vaccine. Most of them lack the knowledge to make an appropriate informed decision about
receiving the vaccine. There are many concerns and questions that may arise when parents,
children, and young adults are asked about receiving the HPV vaccine. It’s important that all of
the barriers to HPV vaccination uptake are known and addressed to help increase the rates of
vaccination for HPV in adolescents and young adults. If the barriers to the uptake of the HPV
vaccine are not addressed, this can have a lasting effect on the future of our young people’s
future sexual, physical and reproductive health (Ferrer, Trotter, Hickman, and Audrey, 2014).
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Case Study
Susie is a 20 year-old female that presents to the University of North Dakota’s clinic on
February 5, 2016 because she would like to start birth control. She is currently a college student
at the University of North Dakota (UND). She does have a primary care provider that she sees
back in her hometown. She states that she is sexually active and uses condoms for protection.
Her last menstrual period was on January 19, 2016. She states her periods are regular and she
bleeds for about five days. She does get occasional cramps but she takes Midol and that seems to
help. She does not have a history of sexual transmitted infections or past pregnancies. She states
she did use Emergency Contraception on January 1, 2016 due to a condom breaking. She states
that she does have some white milky vaginal discharge. She would also like testing for sexually
transmitted diseases today. She states she would like to go on “the pill.”
A thorough history was obtained from Susie during the visit. She is overall a very healthy
young female. She does not have any significant past medical history. She has not had any
surgeries. Susie states that she takes a multivitamin, when she remembers, and reports using
over-the-counter Xenadrine for weight loss on occasion. She has an allergy to Penicillin, but
does not recall the reaction to the medication. She states the reaction happened as a child and all
she knows is her mother told her she is allergic. Susie’s immunizations are up-to-date as
recommended by the CDC, except she reports not having the HPV vaccine and is not sure why
she hasn’t had it. In regards to family history she reports that her mother had a breast mass that
was removed, but it was benign. She also reports that her father had a blood clot after he was
involved in an accident where he hit that area of his leg on impact. Susie is a college student at
UND in the nursing program. She denies smoking, but reports using occasional alcohol on
weekends and denies illicit drug use. She is sexually active with male partners and currently uses
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condoms for protection against pregnancy and sexually transmitted infections (STI’s). Susie
states that she maintains good grades, eats a healthy diet, and exercises regularly.
A comprehensive review of systems was obtained from Susie and was found to be mostly
negative with the exception of a few complaints. She does deny unintentional weight loss or
gain, but reports using Xenadrine on occasion to maintain an acceptable weight for herself. Susie
complains of a white milky vaginal discharge that started a few weeks ago. She denies any odor,
dysuria, itching, hematuria, frequency, or back pain. Susie last had sexual intercourse around
New Year’s Eve when she reports the condom breaking so she used emergency contraception to
prevent pregnancy. She states she has never had an STI as far as she can remember, but has also
never been tested. She reports seeing her primary care provider in her hometown yearly, but has
never had a Papanicolau test (PAP), due to her age. She did not receive the HPV vaccine series,
but is not sure why she did not get it. Susie reports that her menstrual cycles have been normal
and she last had her cycle around January 19, 2016 for about five days. She denies any past
history of oral contraceptives other than the emergency contraceptive she used at the beginning
of January 2016.
A physical exam was performed on Susie. Vital signs were obtained before her visit and
her blood pressure was 122/74 mm/hg, pulse 82 bpm, respiratory rate 18 bpm, and temperature
98.5 degrees Fahrenheit. Her weight was recorded at 110 pounds and height was five feet seven
inches. Her vital signs were all within normal limits, except her Body Mass Index (BMI) was
calculated and found to be 17.2, which falls into the category of underweight (Center for Disease
Control, 2015). Susie’s exam was essentially negative. She was a well-appearing female in no
acute distress. Her head, eyes, ears, nose and throat were all unremarkable. Susie’s neck was
supple with no lymphadenopathy or thyromegaly. Her lungs were clear bilaterally with no
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adventitious sounds or dyspnea. Susie’s heart rate was regular with no extra beats noted. Heart
sounds S1 and S2 were normal and no murmurs were noted upon examination. Abdomen was
soft and non-distended; bowel sounds were present in all four quadrants. Neurologically she was
grossly intact with good balance and coordination. Her skin was warm and pink without rashes.
She had strong pulses bilaterally and no edema was appreciated. A pelvic exam was not
performed due to the situation, but a swab for TYM due to her complaint of white milky
discharge from the vagina and history of sexual activity and recent incident of condom breaking
during intercourse.
After reviewing Susie’s history, review of systems, and completing a good physical
exam, the plan of care for her is to obtain a TYM culture and urine to screen for chlamydia and
gonorrhea due to milky white discharge and past sexual history. Her urine will also be checked
for signs of a urinary tract infection. A urine pregnancy test was also done because Susie would
like to start her birth control pill immediately and not wait for her next period, as recommended
by current guidelines. Her urine was negative for chlamydia and gonorrhea, infection, and
pregnancy. Her TYM swab was also negative. She has no contraindications to start the oral birth
control pill, so Susie will be started on a monophasic oral contraceptive. She was instructed to
start the pill pack on Sunday and use a form of back-up birth control for seven days. She was
educated on oral contraceptives and how they do not prevent STIs, so she should still use
condoms. She was also educated on side effects of the medication and a chart was given to guide
her in the unfortunate event that she missed a pill or two. Susie was educated on HPV and HPV
vaccine and offered the vaccination. All her questions were answered and she was encouraged to
call with any other questions. Susie was informed that she could come in at any time if she
decides that she would like the HPV vaccine and the series would be started for her. She is aware
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that if she wants the vaccine she needs to get it before age 26. The majority of the visit was spent
on education. She was encouraged to make an appointment with her preferred provider for her
Pap test, because she should have it done when she turns 21. Susie was encouraged to return to
clinic or call if she has any other concerns.
Literature Review
The purpose of the literature review was to identify what the barriers are to adolescents
and young adults receiving the HPV vaccine. As mentioned before, the HPV vaccine protects
against cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancers and precancers, along
with genital warts and recurrent respiratory papillomatosis (Centers for Disease Control and
Prevention, 2015). Susie is a 20 year-old college student who has still not received her HPV
vaccine and it has never been offered to her. It’s important that providers understand the barriers
so they can identify the patients that are at higher risk for contracting HPV, along with the
recommended age groups that are eligible to receive the vaccine. If providers gain a better
understanding of the reasons that patients are foregoing the HPV vaccine they can provide better
education so the patient and/or parents can make an informed decision regarding the HPV
vaccine.
The review of literature was done by means of the internet through The Harley French
Library of the Health Sciences online. The search engines utilized were the Cumulative Index of
Nursing and Allied Health Literature (CINAHL) and PubMed. The articles were all within the
last ten years, since 2006 was when the first HPV vaccine was approved. The search terms used
were HPV, Gardasil, vaccine, immunization, attitudes, barriers, belief, safety, concerns,
adolescents, and young adults. There were 26 resources found and reviewed and it was narrowed
down to a total of 16 resources that were pertinent to this review of literature.
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Attitudes toward the HPV vaccine
Most women have positive attitudes regarding the HPV vaccine and intend to receive the
vaccine. In the issue regarding minors, studies show that most parents intend on giving the
vaccine to their child. Parents and adolescents are more likely to get the HPV vaccine if their
provider recommends it and the vaccine is publicly funded. The HPV vaccine has higher uptake
in patients with a history of gynecological disease, with mothers who have experienced cancer in
the family, and those patients that smoke and belong to lower-income families. (Z. Chan, T.
Chan, and Wong, 2012). Slomovitz and Bodurka (2007) reveal a study that asked the parents of
children ages 10-15 years of age if they are going to consent to the HPV vaccine for their child.
The study reported that 55% of parents had intended to give their child the vaccine. The parents
were then given an educational session on the HPV vaccine and the disease and after the session
another 20% of parents were willing to give their child the vaccine. (Slomovitz and Bodurka,
2007).
Warner et al. (2015) did a study on Latino parents’ perceptions of the HPV vaccine.
Latinas have the highest risk of cervical cancer, so prevention is very important. Parents reported
that they were very misinformed about the vaccine. Some admit they didn’t know that males
needed to be vaccinated too, they were unaware of what age groups needed to be vaccinated, and
they did not know that the vaccine was a series of three injections (Warner et al., 2015).
Adolescents that have not yet been sexually active are the prime targets for education on
the HPV vaccine. The vaccine is most effective when given to those adolescents that have not
yet had sexual relations. Some parents believe that their child does not need the vaccine because
they are not sexually active, but they need to be informed that this is the best time to vaccinate
(Slomovitz and Bodurka, 2007).

BARRIERS TO RECEIVING THE HUMAN PAPILLOMA VACCINE

12

Safety and Efficacy
There were extensive safety trials before licensure of HPV4, HPV2, and HPV9. No
significant reactions or concerns were identified; however there is a risk of local reactions and
syncope after receiving HPV4. Patients that are receiving these vaccines should remain sitting or
lying and should be monitored for fifteen minutes after the vaccine is administered. There were
studies done on potential adverse events such as pregnancy outcomes, autoimmune conditions,
demyelinating and other neurological conditions, anaphylaxis, thromboembolic problems, and
stroke. Their post-vaccine rates for these problems were not found to be any different from
background rates (American College of Pediatricians, 2016). More than 40 million doses were
administered in the first five years of routinely vaccinated girls in America and no vaccinespecific adverse effect, with the exception of rare anaphylaxis to vaccine components were
detected (American Academy of Pediatrics, 2012).
A Warner et al. (2015) study that looked at Latino parents’ perception of the HPV
vaccine had high levels of concern about adverse effects that the vaccine may cause. Their
biggest concerns were that the vaccine could cause infertility, death, irregular menstruation, and
behavioral issues. They believed the HPV vaccine was dangerous and could cause serious
complications for their child. Once the parents were properly educated on HPV and the benefits
and risks of the vaccine, they were more willing to consent to vaccinate their child. Most parents
just needed more information on the vaccine, because they had never been properly educated
(Warner et al., 2015).
Parents and patients need to be reminded by their healthcare provider that the HPV
vaccine is highly effective and it’s one of the best defenses we have against cervical cancer.
There are many negative media reports on the HPV vaccine and the potential side effects. Most
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media reports are exaggerated and not true, but this still puts doubt in the patient and parents
minds. The risk of receiving the vaccine is minimal and the benefit is enormous. Healthcare
providers need to be knowledgeable of the HPV vaccine and its safety and efficacy to be able to
educate parents and patients so they can make an informed decision regarding vaccination (Z.
Chan et al., 2012). Short et al. (2010) reported that in their study they interviewed parents of
adolescents regarding the HPV vaccine and found that most of the education on HPV and the
HPV vaccine was received through the media or news reports. Because the source of education is
not reliable and is often inaccurate, there are many parents, adolescents, and young adults that
are misinformed about HPV and the HPV vaccine. Healthcare professionals really need to step it
up and provide good education and work with the media to ensure that everyone is getting
accurate information about HPV and the vaccine (Short et al., 2010).
Parents and adolescents are fearful of the HPV vaccine due to the newness of the vaccine.
They are concerned about long-term effects from the vaccine (Todorova et al., 2014). According
to Okoronkwo, Sieswerda, Cooper, Binette, and Todd (2012) parents that are declining the HPV
vaccine for their children do not trust the HPV vaccine. They are concerned about the lasting
health problems that the vaccine could cause, because its safety is “unproven” and also are wary
of the government’s approval as a guarantee for safety because they believe the vaccine is being
pushed for monetary gain for the pharmaceutical companies. (Okoronkwo et al., 2012).
The CDC has concluded that the HPV vaccine is safe and effective and the benefits
definitely outweigh the risks. The HPV vaccine has proven to be effective in prevention of
cervical cancer along with decreasing the number of genital wart diagnoses. In countries where
the vaccine is free and vaccination rates are higher, they are seeing fewer incidences of genital
warts and less cervical abnormalities on yearly Pap tests. They have also concluded that it is safe
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to give the Gardasil vaccine along with the rest of the recommended adolescent vaccines (Haupt
and Sings, 2011).
Cost and Time
Financial barriers were reported by many parents and young adults regarding the HPV
vaccine. In the United States, most insurance companies are covering the cost of the vaccine.
The vaccine is too expensive for those individuals that do not have insurance, and in return these
individuals are not being vaccinated. Some parents, adolescents, and young adults agree that if
the cost of the vaccine was covered by the government they would be more inclined to consent to
get the vaccine. Studies show that if the vaccine was offered for free, this barrier would not exist
(Ferrer, Trotter, Hickman, Audrey, 2014).
Haupt and Sings (2011) reported that Australia was one of the first countries to
implement free HPV vaccines. They gave Gardasil vaccines to girls in school and to women
younger than 27 years of age. They achieved vaccination rates of approximately 70%. They saw
a decrease in genital warts diagnoses and also a significant reduction in the incidence of high
grade cervical abnormalities in women aged 18-20 years. The HPV vaccine is very beneficial,
but the cost of it can be a huge barrier to the uptake of the vaccine. (Haupt and Sings, 2011). The
cost of the vaccine per dose can be up to 130 dollars or more (Gerend, M. Shepherd and J.
Shepherd, 2013).
The cost of transportation to the clinic to receive the vaccine was also found to be a
common barrier to why adolescents and young adults are not receiving the HPV vaccine. The
HPV vaccine is a series of three injections given over a six month period, so the recipient of the
vaccine would need to report to the clinic several times (Short et al., 2010). This has become an
important barrier that needs to be overcome. Offering the vaccine in schools, workplaces or in
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the pediatrician’s office when they take their children in for appointments would help to
overcome this barrier and help increase the rates of HPV vaccine uptake (Short et al., 2010).
Gerend et al. (2013) did a study on the perceived barriers of the HPV vaccine and they identified
cost and time constraints to be a more identified barrier for those that intended on getting the
HPV vaccine from the start. If the patient or parent did not intend or were undecided about
consenting to the vaccine their biggest concerns were safety and efficacy (Gerend et al., 2013).
Okoronkwo et al. (2012) reported a study from Canada that examined the effects of
knowledge and attitudes of parents toward the HPV vaccine when it was offered free to students
in a school-based setting. The vaccine was publicly funded and given at school only if the
parents consented. The vaccine was not mandated for school-entry. The barrier of cost and time
constraints were overcome, but parents still chose not to vaccinate due to safety concerns. The
study concluded that the parents who did not consent felt that the risks of receiving the vaccine
outweighed the benefits (Okoronkwo et al., 2012).
To overcome the barriers of cost, providers should inform the parents and/or patient
about the Vaccines For Children (VFC) program. It is a federally funded program that provides
vaccines that are recommended by the Advisory Committee on Immunization Practices (ACIP)
to children ages 0-17 at no cost. The children that qualify for these vaccines are children who do
not have insurance, are on Medicaid, or are underinsured. The CDC buys vaccines at a discount
and distributes them to state health departments and public health agencies that give them to
private or public health clinics to give to those children that are eligible for VFC vaccines. The
HPV vaccine is part of this program (Centers for Disease Control and Prevention, 2016). They
would still have the barrier of time constraints, but if the parent knew that the vaccine was free of
charge, the hope would be that this would help increase the uptake of the HPV vaccine. Parents
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and patients are usually not aware that the VFC program exists, so understanding what the
reasons are that the adolescents are not being vaccinated will help guide the provider’s
education.
Not required for school-entry
In the United States, mandatory vaccines for school-entry are decided on a state level for
each state. HPV vaccine is not mandatory for entry to school due to the fact that it is not
transmittable from person to person during the school day. It is only transmitted during sexual
contact. Some healthcare providers feel that making the HPV vaccine a school-entry mandate
would help increase our vaccination rates in adolescence and decrease some of the concerns that
parents have regarding the importance of the vaccine. The belief among parents seems to be that
if the school does not mandate the vaccine, it must not be necessary for my child to receive it.
Some parents in the study felt that mandating the vaccine for school-entry would help to get
more adolescents vaccinated and therefore result in greater benefit for the children (Ferrer et al.,
2014).
Z. Chan et al. (2012) states that vaccination uptake for the HPV vaccine is increased
when the vaccine is publicly funded and provided in a school-based setting. Parents are more
accepting of the vaccine when it is given at school and they tend to be less worried about safety
and efficacy (Z. Chan et al., 2012).
Increased Sexual Promiscuity
Some healthcare providers find it uncomfortable to talk about sexual intercourse with
adolescents, and this is a huge barrier when the intention of the HPV vaccine is too implement it
before the onset of sexual activity. Healthcare providers say that the HPV vaccine is hard to
discuss with adolescents and parents, because most parents do not want to accept that their child
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is or will be engaging in sexual activity. Some of the studies revealed that parents would delay
the vaccine until their children were older, and at an age that they felt their child would be
sexually active. There was also concern among parents that if they gave their adolescent the
vaccine it would give them the “green light” to become sexually active. Some adolescents voiced
opinions about the vaccine and they thought they were completely protected against all sexually
transmitted infections. This raised concerns among parents and healthcare providers. Education
needs to be done with patients and parents before the vaccine is given. Some of the parents
wanted to give the vaccine to their children but did not want to discuss sex with them. They just
wanted to tell their child that they were getting “a shot” to protect them from cancer (Ferrer et
al., 2014).
Healthcare Provider knowledge and recommendation
Parents agree that when their healthcare provider is recommending the vaccine, they are
more likely to give their child the vaccine. If the provider tells the parent the vaccine is available
for their child at age eleven but doesn’t strongly recommend it, parents are more likely to forego
the vaccine. Some providers do not recommend the vaccine because of the concerns of safety.
There are a small number of providers that don’t routinely recommend the HPV vaccine since it
is not required for school-entry. They figure if the parent really wants it they will bring it up at
the appointment (Ferrer et al., 2014).
Healthcare providers seem to be recommending the HPV vaccine based on a perceived
risk to older adolescents and are not recommending it in younger adolescents at age eleven or
twelve. Healthcare providers need to be educated better and understand the importance of
recommending the vaccine before the adolescent becomes sexually active. It is best to catch
them as early as possible. Studies show that parents respect the recommendation of their
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healthcare provider and if they recommend doing the vaccine at a younger age, the parent will
most likely consent. Healthcare providers will benefit from education on the HPV vaccine and
the current recommendations for it (Holman et al., 2014).
Rosberger, Krawczyk , Stephenson, and Lau (2014) did a study that examined
knowledge, attitudes, and beliefs of community based health educators and counselors regarding
the HPV vaccine. They gave the participants questionnaires before and after the two hour
workshop, specifically on the HPV vaccine. Before the workshop most participants had moderate
knowledge of HPV and the vaccine, and they did not feel confident discussing it with parents
and/or patients. They provided them with knowledge and recommendation on HPV and the
vaccine during a two hour workshop. After the workshop their confidence in being able to
provide accurate information to parents and/or patients and willingness to recommend the
vaccine significantly increased. The workshop also helped reduce anxiety about possible side
effects of the vaccine. They were educated on the safety and efficacy of the vaccine and were
able to pass their knowledge on to patients and parents and help increase uptake of the HPV
vaccine. The “potential” side effects of the vaccine are one of the primary reasons why parents
are not vaccinating their children with the HPV vaccine (Roseberger et al., 2014).
In the 2015 study by Warner et al., regarding the perception of Latino parents on the HPV
vaccine, parents agree that healthcare providers are highly influential on the parents’ decision to
vaccinate their child. The parents state they trust their providers and know that they are getting
accurate information regarding the vaccine. The parents in the study who decided not to
vaccinate their child report that their provider did not offer it to them, so they didn’t think it was
important. There were some parents that did speak to their providers about the vaccine but the
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provider did not prioritize the vaccine and offered it as optional, so they didn’t find it important,
and therefore didn’t consent to the vaccine for their child (Warner et al., 2015).
Todorova, Alexandrova-Karamanova, Panayotova, Dimitrova, and Kotzeva (2014)
reported a study they did to understand how the HPV vaccine is perceived by health care
providers in Bulgaria. Health care providers in Bulgaria were excited about the HPV vaccine,
since cervical cancer mortality rates were on the rise. The HPV vaccine gives the providers hope
for the future. Health care providers are in the position to educate parents and patients on the
vaccine, and to do this education they need to be well educated themselves. Health care
providers in Bulgaria feel responsible for reducing fears and uncertainties among patients and
parents, by doing proper education on HPV and the vaccine, by doing so they are hoping to
increase the rates of HPV vaccine uptake (Todorova et al., 2014).
Knowledge Deficit
Many parents report that they do not have the proper knowledge regarding the vaccine to
be able to consent for their child to receive the vaccine. Parents would like more information
about the vaccine and the safety, adverse effects, and current age recommendations.
Communication is important between the healthcare provider and the parent and patient. There is
a belief among parents and adolescents that only sexually active adolescents need the vaccine,
and this belief can cause decrease uptake. Vaccinating adolescents at age eleven or twelve not
only targets adolescents at an age where most are not sexually active yet, but this is the age when
the immune system response to the vaccine is greater (Holman et al., 2014). If the proper
education is given to the parent it helps them make an informed decision regarding the vaccine,
instead of relying on the media, internet stories, and word of mouth.
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Habel, Liddon, and, Stryker (2009) did a study that reviewed the internet for information
regarding the HPV vaccine. They found that the HPV vaccine is being mostly marketed as a
vaccine to prevent cervical cancer, so it is not targeting the male population. They also noted
incomplete information and inaccuracies in information that was provided online. There are quite
a few articles on the internet that question the safety of the vaccine. The public health experts
should be readily available to answer questions that the public has regarding the safety of the
vaccine. Public health experts should be doing a better job of putting accurate information online
and keeping it up to date. They should put more effort into how the media coverage and exposure
affects the vaccination rates (Habel, Liddon and, Stryker, 2009).
There is belief among the some Latino parents that healthcare providers should give
lectures in schools to parents and their children to help learn the importance of the vaccine and
its benefits, some even believe that it should be integrated into the sexual education classes, so
the adolescents are getting the correct information from an accurate source. Educational
materials should be offered in all languages, not just English (Warner et al., 2015).
Gerend et al. (2013) stated that parents that did not intend to consent to the HPV vaccine
argued that there was no need for the vaccine because their child was not sexually active. Parents
argued that if they consented to give the HPV vaccine to their child at such a young age, they
were giving them permission to become sexually active. Some parents were not ready for the sex
conversation that early in their child’s life. Education should be tailored to the concerns of the
parent and/or patient. If they express concern about safety the provider could focus on reducing
those concerns through education. If the concern was cost or time constraints, the provider could
focus on finding a good time and place to do the vaccine, or refer them to other clinics that offer
the vaccine at a reduced rate or participated in VFC (Gerend et al., 2013).
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Religious and Cultural Concerns
Religious and cultural concerns are raised when talking about the HPV vaccine. Some
women believe that cultural and religious mores can play a role in whether or not they receive
the HPV vaccine. Religions and cultures that don’t believe in sex before marriage are refusing
the vaccine, because they don’t want their child to think that receiving the vaccine gives them the
right to start becoming sexually active. They also believe that there is no need for the vaccine if
they aren’t sexually active. A reminder that the vaccine needs to be given before the child
becomes sexually active is important (Short et al., 2010).
In the study regarding Latino parents’ perception regarding the HPV vaccine, parents
reported that their religious beliefs were very influential in their decision to vaccinate. If their
religion didn’t believe in sex before marriage then they usually didn’t consent to vaccinate their
children (Warner et al., 2015). It’s important to note that the CDC reported that 62.3% of females
in the United States have started sexual relations by the twelfth grade, 27.9% by ninth grade, and
4.2% by age 13 (Slomovitz and Bodurka, 2007).
The review of literature identified the reasons why adolescents and young adults, both
male and female, are not receiving the HPV vaccine. The barriers to receiving the HPV vaccine
in adolescents and young adults included attitudes toward the vaccine, cost and time constraints,
safety and efficacy, knowledge deficit regarding the vaccine and disease, provider knowledge
and recommendations of HPV vaccine, vaccine not required for school entry, increased sexual
promiscuity with initiation of vaccine, and religious and cultural beliefs.
To help increase vaccination rates, providers need to be aware of these barriers that they
will encounter in their practice, so they can be prepared to educate patients and parents.
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Learning Points
The review of literature identified some important learning points.
1. Education is key when it comes to vaccinations. The majority of the parents,
adolescents and young adults are misinformed regarding the HPV vaccine. There
needs to be more resources online and through the media that gives complete and
accurate information on the HPV vaccine. Health care providers should offer
educational sessions in their community regarding the benefits to the HPV vaccine.
2. The provider is very influential in the decision making process on whether parents are
going to consent to the HPV vaccine for their child. Providers need to be well
educated and be able to answer all the parents’ questions, along with calming their
fears. The provider should be helping the parent and/or patient weigh the risk and
benefits associated with receiving the HPV vaccine. The provider should have written
education to give to the parents and/or patients and it should be available in different
languages.
3. Patients and/or parents need to be aware of the Vaccines for Children (VFC) program
that is funded through the state. The state of North Dakota has a VFC program that
provides vaccines free of charge for those children under the age of 18 that are
underinsured, Medicaid, or have no insurance. Cost was a huge barrier for those
patients who wanted to receive the vaccine, but couldn’t afford it. By making them
aware of the state funded program for vaccines this will hopefully help increase
vaccine uptake.
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4. HPV is a preventable disease that hopefully can someday be eradicated with
increased vaccination rates. Health care providers need to properly educate parents
and patients to help increase uptake of the HPV vaccine.
5. Making the HPV vaccine more available in different areas, other than just the primary
care clinic could greatly increase the vaccination rates. If the vaccine could be
integrated into schools to be given by the school nurse, for those with parental
consent, could help us reach the adolescents that are being missed in the clinic setting.
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